Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q2 2022 Earnings Presentation
27 slides from Indivior Pharmaceuticals's earnings presentation, Jul 28, 2022
Slide 1: Indivior PLC Q2 2022 Results
Indivior PLC Q2 2022 Results July 28, 2022
Slide 2: Agenda
AGENDA Overview & Strategic Priorities Update Mark Crossley Q2 / H1 Performance & FY 2022 Guidance Ryan Preblick R&D Update Christian Heidbreder Conclusion Mark Crossley Q&A All
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Forward-looking statements
Forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group’s financial guidance for 2022 and its medium- and long-term growth outlook, the potential for an addition
Slide 5: Q2 2022 key messages
Q2 2022 key messages Strong overall performance led by SUBLOCADE® growth; execution on Strategic ( Priorities continues Raising FY 2022 net revenue guidance for SUBLOCADE®; total Group net revenue and adj. operating income expectations maintained >$1 bil. gross cash and investments1; disciplined app
Slide 6: Strategic Priorities update: Q2 2022
Strategic Priorities update: Q2 2022 Grow SUBLOCADE® Diversify Build Our Optimize >$1 bil. Revenue Pipeline Operating Model Q2 22 NR: $98m PERSERIS® Aelis Farma (AEF 0117) Q2 22 Adj. Operating Profit1: Q2 22 NR: $7m Cannabis Use Disorder: Phase +15% vs. Q1 22 $60m 2b study initiated Q2 22; other +81
Slide 7: OHS Strategy focused on SUBLOCADE prescribing depth
OHS Strategy focused on SUBLOCADE prescribing depth Early OHS cohorts show steady increases in HCPs prescribing for 5+ patients Driving deeper prescribing in OHS accounts Achieved access to 500+ OHS Facilities (not incl. CJS) • Drive access to OHS children priority OHS parents Prescribing OHS HCPs •
Slide 8: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 9: Q2 2022 financial highlights
Q2 2022 financial highlights Takeaways Profit & Loss ($ in mil. actual F/X) ➤ Double-digit top-line growth Q2 22 Q2 21 Change ➤ SUBLOCADE NR up 81% YOY1 US Net Revenue $179 $154 16% ROW Net Revenue $42 $47 -11% ➤ PERSERIS traction with NR up 75% Total Net Revenue $221 $201 10% YOY Key product NR SUB
Slide 10: Cash & Borrowing position
Cash & Borrowing position Cash & Borrowing table Takeaways Total gross cash & investments of $1,015m1: ➤ Strong cash generation from operations (excluding ($ in mil.) Q2 22 FY 21 litigation settlement payments in H1) ➤ ANDA litigation payment in Q2 with July’22 return of Cash & Cash Equivalents $857
Slide 11: FY 22 guidance – SUBLOCADE NR expectations raised
FY 22 guidance – SUBLOCADE NR expectations raised; total Group guidance maintained Additional top-line items ➤ Underlying BMAT market growth of mid- to high-single digits ➤ US SUBOXONE® Film FY 22 Guidance1 ($ in mil.) • Potential market impact to the US sublingual film market in H2 from launch of 4
Slide 12: Christian Heidbreder, Chief Scientific Officer
Christian Heidbreder Chief Scientific Officer
Slide 13: Pipeline progress
Pipeline progress • Phase 2b, randomized, double-blind, placebo-controlled, 4-arm, parallel-group, prospective, multicenter study in treatment-seeking Phase 2 Cannabis Use Disorders (CUD) subjects with moderate to severe cannabis use disorder (CUD), according to DSM-5 criteria: First Subject First V
Slide 14: Global cannabis use
Global cannabis use The number of cannabis users aged 15–64 has increased by 23% over the past decade - Rising Δ9-THC & falling CBD levels amplify health risks 209 million or 4% of the global population Source: UNODC, World Drug Report 2022 (United Nations publication, 2022) 14
Slide 15: Cannabis users and Cannabis Use Disorder in US
Cannabis users and Cannabis Use Disorder (CUD) in US people Aged 12> (2020) 49.6 million used cannabis over the past year 14.2 million had CUD over the past year Source: Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United St
Slide 16: Long-term consequences of persistent cannabis use
Long-term consequences of persistent cannabis use 16
Slide 17: Appendix
Appendix ocus on you.
Slide 18: SUBOXONE sublingual film indication and safety information
SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND USAGE SUBOXONE® Film is indicated for treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support HIGHLIGHTED SAFETY INFORMATION Prescr
Slide 19: SUBLOCADE indication and safety information
SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment f
Slide 20: About PERSERIS indication and safety information
ABOUT PERSERIS® (risperidone) for extended-release injectable suspension INDICATION PERSERIS® (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed w
Slide 21: Income statement: Q2 2022 vs. Q2 2021
Income statement: Q2 2022 vs. Q2 2021 Q2 2022 Q2 2021 Δ Q2 2022 Q2 2022 Y-o-Y Q2 2021 Q2 2021 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 221 221 201 201 Cost of Sales (38) (38) (30) (30) Gross Profit 183 183 171 171 Gross Margin (%
Slide 22: Income statement: H1 2022 vs. H1 2021
Income statement: H1 2022 vs. H1 2021 H1 2022 H1 2021 Δ Q2 2022 Q2 2022 Y-o-Y Q2 2021 Q2 2021 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 428 428 381 381 Cost of Sales (75) (75) (62) (62) Gross Profit 353 353 319 319 Gross Margin (%
Slide 23: H2 2022 Capital Markets Calendar
H2 2022 Capital Markets Calendar Date Key Event Morgan Stanley Healthcare Conference New York Sept 12th – 13th • Fireside chat • 1:1s Bank of America Healthcare Conference London Sept 15th – 16th • Presentation & 1:1s Oct 27th – Nov 2nd Q3 22 Results Earnings Call & Investor Roadshow Stifel Healthca
Slide 24: Indivior Capital Markets Day – Save the date
Indivior Capital Markets Day – Save the date Indivior senior executives will present a detailed outlook and execution path for delivering the Group’s strategic priorities. The meeting will include live question and answer sessions. When: Wednesday, December 7th Where: New York City (Webcast will be
Slide 25: Peer-reviewed publications H1-2022
Peer-reviewed publications H1-2022 https://doi.org/10.1371/journal.pone.0256752 https://doi.org/10.1016/j.drugalcdep.2022.109389 83 news stories from 46 news outlets https://doi.org/10.1016/j.drugpo.2021.103492 https://doi.org/10.1172/jci.insight.156973 https://doi.org/10.1007/7854_2022_347 25
Slide 26: Conferences H1-2022
Conferences H1-2022 Poor mental health is associated with higher JAN levels of poverty, poor physical health, low education, lack of internet access., use of Providers and payers perceive that food stamps, and incarceration. Areas of patients with OUD experienced worse highest need lack access t
Slide 27: Thank you
you. Focus on VIOR al Z Nz AN